FDA guidance delays increase by 20% under new commissioner

Drug approval timelines will extend by an average of 20% in the first 12 months under the new FDA commissioner due to increased scrutiny and guideline revisions. This contradicts short-term market optimism.

Implied probability (Yes)

55%